Update on tuberculosis: TB in the early 21st century

European Respiratory Review

Volumn 20, Issue 120, 2011, Pages 71-84

  Connell, D W ^a   Berry, M ^a,b   Cooke, G ^c   Kon, O M ^a  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; BCG VACCINE; BEDAQUILINE; CIPROFLOXACIN; DELAMANID; DEXAMETHASONE; EFAVIRENZ; ETHAMBUTOL; GAMMA INTERFERON; GLUCOCORTICOID; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; IMIPENEM; INTERLEUKIN 4; ISONIAZID; KANAMYCIN; LINEZOLID; LIPOARABINOMANNAN; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLACEBO; PNU 100480; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL TRANSMISSION; BACTERIUM CULTURE; BIOMASS; CIGARETTE SMOKING; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOBRONCHIAL ULTRASONOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; EUROPE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; MIGRATION; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NUCLEIC ACID AMPLIFICATION; SPUTUM SMEAR; TRANSBRONCHIAL ASPIRATION; TUBERCULOSIS; TUBERCULOSIS CONTROL; TUBERCULOUS LYMPHADENITIS; TUBERCULOUS MENINGITIS; UNSPECIFIED SIDE EFFECT; VITAMIN D DEFICIENCY;

ANTITUBERCULAR AGENTS; COMMUNICABLE DISEASE CONTROL; EUROPE; HIV INFECTIONS; HUMANS; LATENT TUBERCULOSIS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH;

EID: 79958281526     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.00000511     Document Type: Article

References (180)

1. World Health Organization. Global Tuberculosis Control 2010. WHO/HTM/TB/2010.7. Geneva, World Health Organization, 2010.
2. Dye C, Scheele S, Dolin P, et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282: 677-686.
3. Mack U, Migliori GB, Sester M, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 2009; 33: 956-973.
4. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974; 99: 131-138.
5. Vynnycky E, Fine PE. Lifetime risks, incubation period, and serial interval of tuberculosis. Am J Epidemiol 2000; 152: 247-263.
6. European Centre for Disease Prevention and Control, World Health Organization. Surveillance Report: Tuberculosis Surveillance in Europe 2008. Stockholm, European Centre for Disease Prevention and Control, 2010.
7. World Health Organization. Multidrug and Extensively Drug- Resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response. WHO/ATM/TB2010.3. Geneva, World Health Organization, 2010.
8. Health Protection Agency. Tuberculosis in the UK: Report on Tuberculosis Surveillance in the UK 2010. London, Health Protection Agency Centre for Infections, 2010.
9. WHO. Global Tuberculosis Control 2009: Epidemiology, Strategy, Financing. Geneva, World Health Organization report, 2009.
10. Raviglione MC. The Global Plan to Stop TB, 2006-2015. Int J Tuberc Lung Dis 2006; 10: 238-239.
11. United Nations. International Migrant Stock: The 2008 Revision. http://esa.un.org/migration/index.asp?panel51.
12. Haase I, Olson S, Behr MA, et al. Use of geographic and genotyping tools to characterise tuberculosis transmission in Montreal. Int J Tuberc Lung Dis 2007; 11: 632-638.
13. Dahle UR, Sandven P, Heldal E, et al. Continued low rates of transmission of Mycobacterium tuberculosis in Norway. J Clin Microbiol 2003; 41: 2968-2973.
14. Borrell S, Espanol M, Orcau A, et al. Tuberculosis transmission patterns among Spanish-born and foreign-born populations in the city of Barcelona. Clin Microbiol Infect 2010; 16: 568-574.
15. Maguire H, Dale JW, McHugh TD, et al. Molecular epidemiology of tuberculosis in London 1995-7 showing low rate of active transmission. Thorax 2002; 57: 617-622.
16. Diel R, Rusch-Gerdes S, Niemann S. Molecular epidemiology of tuberculosis among immigrants in Hamburg, Germany. J Clin Microbiol 2004; 42: 2952-2960.
17. Codecasa LR, Porretta AD, Gori A, et al. Tuberculosis among immigrants from developing countries in the province of Milan, 1993-1996. Int J Tuberc Lung Dis 1999; 3: 589-595.
18. Diz S, Lopez-Velez R, Moreno A, et al. Epidemiology and clinical features of tuberculosis in immigrants at an infectious diseases department in Madrid. Int J Tuberc Lung Dis 2007; 11: 769-774.
19. Dasgupta K, Menzies D. Cost-effectiveness of tuberculosis control strategies among immigrants and refugees. Eur Respir J 2005; 25: 1107-1116.
20. Rose AM, Watson JM, Graham C, et al. Tuberculosis at the end of the 20th century in England and Wales: results of a national survey in 1998. Thorax 2001; 56: 173-179.
21. Smieja MJ, Marchetti CA, Cook DJ, et al. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000; 2: CD001363.
22. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis 1992; 145: 36-41.
23. Moore-Gillon J, Davies PD, Ormerod LP. Rethinking TB screening: politics, practicalities and the press. Thorax 2010; 65: 663-665.
24. Alvarez GG, Gushulak B, Abu Rumman K, et al. A comparative examination of tuberculosis immigration medical screening programs from selected countries with high immigration and low tuberculosis incidence rates. BMC Infect Dis 2011; 11: 3.
25. Klinkenberg E, Manissero D, Semenza JC, et al. Migrant tuberculosis screening in the EU/EEA: yield, coverage and limitations. Eur Respir J 2009; 34: 1180-1189.
26. Liu Y, Weinberg MS, Ortega LS, et al. Overseas screening for tuberculosis in U.S.-bound immigrants and refugees. N Engl J Med 2009; 360: 2406-2415.
27. Pareek M, Abubakar I, White PJ, et al. TB screening of migrants to low TB burden nations: insights from evaluation of UK practice. Eur Respir J 2010; [Epub ahead of print DOI: 10.1183/09031936.00105810].
28. Hardy AB, Varma R, Collyns T, et al. Cost-effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the QuantiFERON-TB Gold IGRA alone is more cost-effective for immigrants from high burden countries. Thorax 2010; 65: 178-180.
29. Orlando G, Merli S, Cordier L, et al. Interferon-c releasing assay versus tuberculin skin testing for latent tuberculosis infection in targeted screening programs for high risk immigrants. Infection 2010; 38: 195-204.
30. Davies PDO, Barnes PJ, Gordon SB. Clinical Tuberculosis. 4th Edn. London, Hodder Arnold, 2008.
31. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010; 36: 1185-1206.
32. Lonnroth K, Raviglione M. Global epidemiology of tuberculosis: prospects for control. Semin Respir Crit Care Med 2008; 29: 481-491.
33. Lonnroth K, Castro KG, Chakaya JM, et al. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet 2010; 375: 1814-1829.
34. Creswell J, Raviglione M, Ottmani S, et al. Tuberculosis and noncommunicable diseases: neglected links, missed opportunities. Eur Respir J 2010; [Epub ahead of print DOI: 10.1183/09031936.00084310].
35. Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 2010; 34: J258-J265.
36. Bates MN, Khalakdina A, Pai M, et al. Risk of tuberculosis from exposure to tobacco smoke: a systematic review and metaanalysis. Arch Intern Med 2007; 167: 335-342.
37. Wen CP, Chan TC, Chan HT, et al. The reduction of tuberculosis risks by smoking cessation. BMC Infect Dis 2010; 10: 156.
38. Lin HH, Ezzati M, Murray M. Tobacco smoke, indoor air pollution and tuberculosis: a systematic review and metaanalysis. PLoS Med 2007; 4: e20.
39. Slama K, Chiang CY, Hinderaker SG, et al. Indoor solid fuel combustion and tuberculosis: is there an association? Int J Tuberc Lung Dis 2010; 14: 6-14.
40. Kolappan C, Subramani R. Association between biomass fuel and pulmonary tuberculosis: a nested case-control study. Thorax 2009; 64: 705-708.
41. Lin HH, Murray M, Cohen T, et al. Effects of smoking and solidfuel use on COPD, lung cancer, and tuberculosis in China: a time-based, multiple risk factor, modelling study. Lancet 2008; 372: 1473-1483.
42. Rehm J, Samokhvalov AV, Neuman MG, et al. The association between alcohol use, alcohol use disorders and tuberculosis (TB). A systematic review. BMC Public Health 2009; 9: 450.
43. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis 2009; 9: 737-746.
44. Jeon CY, Harries AD, Baker MA, et al. Bi-directional screening for tuberculosis and diabetes: a systematic review. Trop Med Int Health 2010; 15: 1300-1314.
45. Davies PD, Brown RC, Woodhead JS. Serum concentrations of vitamin D metabolites in untreated tuberculosis. Thorax 1985; 40: 187-190.
46. Wilkinson RJ, Llewelyn M, Toossi Z, et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study. Lancet 2000; 355: 618-621.
47. Nnoaham KE, Clarke A. Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis. Int J Epidemiol 2008; 37: 113-119.
48. Martineau AR WK, Newton SM, Floto RA, et al. IFN-c- and TNFindependent vitamin D-inducible human suppression of mycobacteria: the role of cathelicidin LL-37. J Immunol 2007; 178: 7190-7198.
49. Liu PT, Stenger S, Tang DH, et al. Cutting edge: vitamin Dmediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J Immunol 2007; 179: 2060-2063.
50. Nursyam EW, Amin Z, Rumende CM. The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion. Acta Med Indones 2006; 38: 3-5.
51. Wejse C, Gomes VF, Rabna P, et al. Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebocontrolled trial. Am J Respir Crit Care Med 2009; 179: 843-850.
52. Martineau AR, Peter MT, Graham HB, et al. High-dose vitamin D3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 2011; 377: 242-250.
53. Broekmans JF, Migliori GB, Rieder HL, et al. European framework for tuberculosis control and elimination in countries with a low incidence. Eur Respir J 2002; 19: 765-775.
54. Holden M, Dubin MR, Diamond PH. Frequency of negative intermediate-strength tuberculin sensitivity in patients with active tuberculosis. N Engl J Med 1971; 285: 1506-1509.
55. Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004; 350: 2060-2067.
56. Lalvani A. Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy. Chest 2007; 131: 1898-1906.
57. Lalvani A, Pathan AA, McShane H, et al. Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigenspecific T cells. Am J Respir Crit Care Med 2001; 163: 824-828.
58. Mori T, Sakatani M, Yamagishi F, et al. Specific detection of tuberculosis infection: an interferon-c-based assay using new antigens. Am J Respir Crit Care Med 2004; 170: 59-64.
59. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149: 177-184.
60. Diel R, Goletti D, Ferrara G, et al. Interferon-c release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011; 37: 88-99.
61. Lalvani A, Pathan AA, Durkan H, et al. Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T-cells. Lancet 2001; 357: 2017-2021.
62. Nakaoka H, Lawson L, Squire SB, et al. Risk for tuberculosis among children. Emerg Infect Dis 2006; 12: 1383-1388.
63. Mutsvangwa J, Millington KA, Chaka K, et al. Identifying recent Mycobacterium tuberculosis transmission in the setting of high HIV and TB burden. Thorax 2010; 65: 315-320.
64. Liebeschuetz S, Bamber S, Ewer K, et al. Diagnosis of tuberculosis in South African children with a T-cell-based assay: a prospective cohort study. Lancet 2004; 364: 2196-2203.
65. Chapman AL, Munkanta M, Wilkinson KA, et al. Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. AIDS 2002; 16: 2285-2293.
66. Lalvani A, Millington KA. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev 2008; 8: 147-152.
67. Passalent L, Khan K, Richardson R, et al. Detecting latent tuberculosis infection in hemodialysis patients: a head-to-head comparison of the T-SPOT.TB test, tuberculin skin test, and an expert physician panel. Clin J Am Soc Nephrol 2007; 2: 68-73.
68. Winthrop KL, Nyendak M, Calvet H, et al. Interferon-c release assays for diagnosing Mycobacterium tuberculosis infection in renal dialysis patients. Clin J Am Soc Nephrol 2008; 3: 1357-1363.
69. Inoue T, Nakamura T, Katsuma A, et al. The value of QuantiFERON TB-Gold in the diagnosis of tuberculosis among dialysis patients. Nephrol Dial Transplant 2009; 24: 2252-2257.
70. Connell DW, Singanayagam A, Charif R, et al. A comparison between interferon c release assays and the tuberculin skin test in the contact tracing of patients with chronic kidney disease. Thorax 2010; [Epub ahead of print DOI: 10.1136/thx.2010.149088].
71. Chia S, Karim M, Elwood RK, et al. Risk of tuberculosis in dialysis patients: a population-based study. Int J Tuberc Lung Dis 1998; 2: 989-991.
72. Raby E, Moyo M, Devendra A, et al. The effects of HIV on the sensitivity of a whole blood IFN-c release assay in Zambian adults with active tuberculosis. PLoS ONE 2008; 3: e2489.
73. Balcells ME, Perez CM, Chanqueo L, et al. A comparative study of two different methods for the detection of latent tuberculosis in HIV-positive individuals in Chile. Int J Infect Dis 2008; 12: 645-652.
74. Brock I, Ruhwald M, Lundgren B, et al. Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-c test. Respir Res 2006; 7: 56.
75. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001; 19: 93-129.
76. Bakir M, Millington KA, Soysal A, et al. Prognostic value of a Tcell- based, interferon-c biomarker in children with tuberculosis contact. Ann Intern Med 2008; 149: 777-787.
77. Aichelburg MC, Rieger A, Breitenecker F, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-c release assay in HIV-1-infected individuals. Clin Infect Dis 2009; 48: 954-962.
78. Diel R, Loddenkemper R, Meywald-Walter K, et al. Predictive value of a whole blood IFN-c assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2008; 177: 1164-1170.
79. Kik SV, Franken WPJ, Mensen M, et al. Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts. Eur Respir J 2010; 35: 1346-1353.
80. Hill PC, Jackson-Sillah DJ, Fox A, et al. Incidence of tuberculosis and the predictive value of ELISPOT and Mantoux tests in Gambian case contacts. PLoS ONE 2008; 3: e1379.
81. Mazurek GH, Jereb J, Lobue P, et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005; 54: 49-55.
82. The National Collaborating Centre for Chronic Conditions. Tuberculosis: clinical diagnosis and management of tuberculosis and measures for its prevention and control. London, Royal College of Physicians, 2006.
83. Kruijshaar ME, Abubakar I. Increase in extrapulmonary tuberculosis in England and Wales 1999-2006. Thorax 2009; 64: 1090-1095.
84. Dosanjh DP, Hinks TS, Innes JA, et al. Improved diagnostic evaluation of suspected tuberculosis. Ann Intern Med 2008; 148: 325-336.
85. Ruhwald M, Bodmer T, Maier C, et al. Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis. Eur Respir J 2008; 32: 1607-1615.
86. Wilkinson KA, Wilkinson RJ, Pathan A, et al. Ex vivo characterization of early secretory antigenic target 6-specific T cells at sites of active disease in pleural tuberculosis. Clin Infect Dis 2005; 40: 184-187.
87. Jafari C, Ernst M, Kalsdorf B, et al. Rapid diagnosis of smearnegative tuberculosis by bronchoalveolar lavage enzyme-linked immunospot. Am J Respir Crit Care Med 2006; 174: 1048-1054.
88. Jafari C, Thijsen S, Sotgiu G, et al. Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis. Am J Respir Crit Care Med 2009; 180: 666-673.
89. Dheda K, van Zyl-Smit RN, Meldau R, et al. Quantitative lung T cell responses aid the rapid diagnosis of pulmonary tuberculosis. Thorax 2009; 64: 847-853.
90. Losi M, Bossink A, Codecasa L, et al. Use of a T-cell interferon-c release assay for the diagnosis of tuberculous pleurisy. Eur Respir J 2007; 30: 1173-1179.
91. Thomas MM, Hinks TS, Raghuraman S, et al. Rapid diagnosis of Mycobacterium tuberculosis meningitis by enumeration of cerebrospinal fluid antigen-specific T-cells. Int J Tuberc Lung Dis 2008; 12: 651-657.
92. Kim SH, Cho OH, Park SJ, et al. Rapid diagnosis of tuberculous meningitis by T cell-based assays on peripheral blood and cerebrospinal fluid mononuclear cells. Clin Infect Dis 2010; 50: 1349-1358.
93. Cashmore TJ, Peter JG, van Zyl-Smit RN, et al. Feasibility and diagnostic utility of antigen-specific interferon-c responses for rapid immunodiagnosis of tuberculosis using induced sputum. PLoS ONE 2010; 5: e10389.
94. Breen RA, Hardy GA, Perrin FM, et al. Rapid diagnosis of smearnegative tuberculosis using immunology and microbiology with induced sputum in HIV-infected and uninfected individuals. PLoS ONE 2007; 2: e1335.
95. Sester M, Sotgiu G, Lange C, et al. Interferon-c release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Respir J 2011; 37: 100-111.
96. Steingart KR, Henry M, Ng V, et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 2006; 6: 570-581.
97. Pathways to better diagnostics for tuberculosis. A blueprint for the development of TB diagnostics by the new diagnostics working group of the Stop TB Partnership. Geneva, Stop TB Partnership, World Health Organization, 2009.
98. Palomino JC. Molecular detection, identification and drug resistance detection in Mycobacterium tuberculosis. FEMS Immunol Med Microbiol 2009; 56: 103-111.
99. Dorman SE. New diagnostic tests for tuberculosis: bench, bedside, and beyond. Clin Infect Dis 2010; 50: Suppl. 3, S173-S177.
100. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363: 1005-1015.
101. World Health Organization. Strategic and Technical Advisory Group For Tuberculosis (STAG-TB). Report of the Tenth Meeting, 2010. WHO/HTM/TB/2010.18. Geneva, World Health Organization, 2010.
102. Wallis RS, Doherty TM, Onyebujoh P, et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis 2009; 9: 162-172.
103. Doherty TM, Wallis RS, Zumla A. Biomarkers of disease activity, cure, and relapse in tuberculosis. Clin Chest Med 2009; 30: 783-796.
104. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8: 247-258.
105. Millington KA, Innes JA, Hackforth S, et al. Dynamic relationship between IFN-c and IL-2 profile of Mycobacterium tuberculosisspecific T cells and antigen load. J Immunol 2007; 178: 5217-5226.
106. Casey R, Blumenkrantz D, Millington K, et al. Enumeration of functional T-cell subsets by fluorescence-immunospot defines signatures of pathogen burden in tuberculosis. PLoS ONE 2010; 5: e15619.
107. Mistry R, Cliff JM, Clayton CL, et al. Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosis. J Infect Dis 2007; 195: 357-365.
108. Jacobsen M, Repsilber D, Gutschmidt A, et al. Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis. J Mol Med 2007; 85: 613-621.
109. Maertzdorf J, Repsilber D, Parida SK, et al. Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immun 2011; 12: 15-22.
110. Berry MP, Graham CM, McNab FW, et al. An interferoninducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010; 466: 973-977.
111. Wu B, Huang C, Kato-Maeda M, et al. Messenger RNA expression of IL-8, FOXP3, and IL-12b differentiates latent tuberculosis infection from disease. J Immunol 2007; 178: 3688-3694.
112. Demissie A, Abebe M, Aseffa A, et al. Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of Th1 cytokines and the IL-4 antagonist IL-4d2. J Immunol 2004; 172: 6938-6943.
113. Siawaya JF, Bapela NB, Ronacher K, et al. Differential expression of interleukin-4 (IL-4) and IL-4 d 2 mRNA, but not transforming growth factor b (TGF-b), TGF-b RII, Foxp3, c interferon, T-bet, or GATA-3 mRNA, in patients with fast and slow responses to antituberculosis treatment. Clin Vaccine Immunol 2008; 15: 1165-1170.
114. Trisolini R, Agli LL, Cancellieri A, et al. The value of flexible transbronchial needle aspiration in the diagnosis of stage I sarcoidosis. Chest 2003; 124: 2126-2130.
115. Bilaçeroǧlu S, Günel O, Eriş N, et al. Transbronchial needle aspiration in diagnosing intrathoracic tuberculous lymphadenitis. Chest 2004; 126: 259-267.
116. Harkin TJ, Ciotoli C, Addrizzo-Harris DJ, et al. Transbronchial needle aspiration (TBNA) in patients infected with HIV. Am J Respir Crit Care Med 1998; 157: 1913-1918.
117. Varela-Lema L, Fernandez-Villar A, Ruano-Ravina A. Effectiveness and safety of endobronchial ultrasound-transbronchial needle aspiration: a systematic review. Eur Respir J 2009; 33: 1156-1164.
118. Gilbert S, Wilson DO, Christie NA, et al. Endobronchial ultrasound as a diagnostic tool in patients with mediastinal lymphadenopathy. Ann Thorac Surg 2009; 88: 896-900.
119. Garwood S, Judson MA, Silvestri G, et al. Endobronchial ultrasound for the diagnosis of pulmonary sarcoidosis. Chest 2007; 132: 1298-1304.
120. Oki M, Saka H, Kitagawa C, et al. Real-time endobronchial ultrasound-guided transbronchial needle aspiration is useful for diagnosing sarcoidosis. Respirology 2007; 12: 863-868.
121. Steinfort DP, Johnson DF, Connell TG, et al. Endobronchial ultrasound-guided biopsy in the evaluation of intrathoracic lymphadenopathy in suspected tuberculosis: a minimally invasive technique with a high diagnostic yield. J Infect 2009; 58: 309-311.
122. Mehta MR, Connell DW, Wickremasinghe MI, et al. The use of thoracic computed tomography scanning and EBUS-TBNA to diagnose tuberculosis of the central nervous system: two case reports. Eur Respir Rev 2010; 19: 345-347.
123. Molyneaux PL, Muttardi K, Connell DW, et al. Clinical utility of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for the diagnosis of mediastinal tuberculous lymphadenitis. Thorax 2009; 64: A120-A127.
124. Goo JM, Im JG, Do KH, et al. Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology 2000; 216: 117-121.
125. Moore DA, Evans CA, Gilman RH, et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med 2006; 355: 1539-1550.
126. Zimic M, Coronel J, Gilman RH, et al. Can the power of mobile phones be used to improve tuberculosis diagnosis in developing countries? Trans R Soc Trop Med Hyg 2009; 103: 638-640.
127. Ha DT, Lan NT, Wolbers M, et al. Microscopic observation drug susceptibility assay (MODS) for early diagnosis of tuberculosis in children. PLoS ONE 2009; 4: e8341.
128. Ha DT, Lan NT, Kiet VS, et al. Diagnosis of pulmonary tuberculosis in HIV-positive patients by microscopic observation drug susceptibility assay. J Clin Microbiol 2010; 48: 4573-4579.
129. Caws M, Dang TM, Torok E, et al. Evaluation of the MODS culture technique for the diagnosis of tuberculous meningitis. PLoS ONE 2007; 2: e1173.
130. Minion J, Leung E, Menzies D, et al. Microscopic-observation drug susceptibility and thin layer agar assays for the detection of drug resistant tuberculosis: a systematic review and metaanalysis. Lancet Infect Dis 2010; 10: 688-698.
131. Hillemann D, Ruesch-Gerdes S, Boehme C, et al. Rapid molecular detection of extrapulmonary tuberculosis by automated GeneXpert(R) MTB/RIF system. J Clin Microbiol 2011; [Epub ahead of print DOI: 10.1128/JCM.02268-10].
132. Peter J, Green C, Hoelscher M, et al. Urine for the diagnosis of tuberculosis: current approaches, clinical applicability, and new developments. Curr Opin Pulm Med 2010; 16: 262-270.
133. Swaminathan S, Padmapriyadarsini C, Narendran G. HIVassociated tuberculosis: clinical update. Clin Infect Dis 2010; 50: 1377-1386.
134. Schutz C, Meintjes G, Almajid F, et al. Clinical management of tuberculosis andHIV-1 co-infection. Eur Respir J 2010; 36: 1460-1481.
135. Sonnenberg P, Glynn JR, Fielding K, et al. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 2005; 191: 150-158.
136. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359: 2059-2064.
137. Getahun H, Harrington M, O'Brien R, et al. Diagnosis of smearnegative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet 2007; 369: 2042-2049.
138. Lawn SD, Kranzer K, Edwards DJ, et al. Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS 2010; 24: 1323-1328.
139. Houlihan CF, Mutevedzi PC, Lessells RJ, et al. The tuberculosis challenge in a rural South African HIV programme. BMC Infect Dis 2010; 10: 23.
140. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008; 8: 516-523.
141. Muller M, Wandel S, Colebunders R, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and metaanalysis. Lancet Infect Dis 2010; 10: 251-261.
142. Meintjes G, Wilkinson RJ, Morroni C, et al. Randomized placebocontrolled trial of prednisone for paradoxical tuberculosisassociated immune reconstitution inflammatory syndrome. AIDS 2010; 24: 2381-2390.
143. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362: 697-706.
144. Boulle A, Clayden P, Cohen K, et al. Prolonged deferral of antiretroviral therapy in the SAPIT trial: did we need a clinical trial to tell us that this would increase mortality? S Afr Med J 2010; 100: 566, 568: 570-571.
145. Blanc FX, Sok T, Laureillard D, et al. Significant enhancement in survival with early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) in severly immunosuppressed HIV-infected adults with newly diagnosed tuberculosis. XVIII Intenational AIDS conference, Vienna, 2010. http://pag.aids2010.org/Abstracts.aspx?AID517091.
146. Maartens G, Decloedt E, Cohen K. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries. Antivir Ther 2009; 14: 1039-1043.
147. Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008; 300: 530-539.
148. Naiker S, Conolly C, Weisner L, et al. Pharmacokinetic evaluation of different rifabutin dosing strategies in African tuberculosis patients on lopinavir/ritonavir based antiretroviral treatment. 18th CROI, Boston, USA, 2011. www.retroconference.org/AbstractSearch/Default.aspx
149. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580.
150. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet, 375: 1798-1807.
151. O'Donnell MR, Jarand J, Loveday M, et al. High incidence of hospital admissions with multidrug-resistant and extensively drug-resistant tuberculosis among South African health care workers. Ann Intern Med 2010; 153: 516-522.
152. Eriksen J, Chow JY, Mellis V, et al. Protective effect of BCG vaccination in a nursery outbreak in 2009: time to reconsider the vaccination threshold? Thorax 2010; 65: 1067-1071.
153. Kaufmann SH, Hussey G, Lambert PH. New vaccines for tuberculosis. Lancet 2010; 375: 2110-2119.
154. Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a doubleblind, randomised, controlled phase II trial. Lancet 2009; 373: 1183-1189.
155. Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174: 331-338.
156. Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009; 180: 273-280.
157. Lienhardt C, Vernon A, Raviglione MC. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Curr Opin Pulm Med 2010; 16: 186-193.
158. Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009; 34: 387-393.
159. Chambers HF, Turner J, Schecter GF, et al. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob Agents Chemother 2005; 49: 2816-2821.
160. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-2405.
161. Hawkey CR, Yap T, Pereira J, et al. Characterization and management of paradoxical upgrading reactions in HIV-uninfected patients with lymph node tuberculosis. Clin Infect Dis 2005; 40: 1368-1371.
162. Breen RA, Smith CJ, Bettinson H, et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 2004; 59: 704-707.
163. Strang JI, Kakaza HH, Gibson DG, et al. Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei. Lancet 1987; 2: 1418-1422.
164. Strang JI, Nunn AJ, Johnson DA, et al. Management of tuberculous constrictive pericarditis and tuberculous pericardial effusion in Transkei: results at 10 years follow-up. QJM 2004; 97: 525-535.
165. Mayosi BM, Ntsekhe M, Volmink JA, et al. Interventions for treating tuberculous pericarditis. Cochrane Database Syst Rev 2002; 4: CD000526.
166. Centers for Disease Control and Prevention. Treatment of tuberculosis. MMWR Morb Mortal Wkly Rep 2003; 52: 1-77.
167. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004; 351: 1741-1751.
168. Prasad K, Singh MB. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev 2008; 1: CD002244.
169. Migliori GB, De Iaco G, Besozzi G, et al. First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill 2007; 12: E070517.1.
170. Velayati AA, Masjedi MR, Farnia P, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 2009; 136: 420-425.
171. Migliori GB, Loddenkemper R, Blasi F, et al. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDRTB threat. Is "science" enough to tackle the epidemic? Eur Respir J 2007; 29: 423-427.
172. Johnston JC, Shahidi NC, Sadatsafavi M, et al. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS ONE 2009; 4: e6914.
173. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
174. Caminero JA, Sotgiu G, Zumla A, et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10: 621-629.
175. Migliori GB, Besozzi G, Girardi E, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 2007; 30: 623-626.
176. Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008; 359: 563-574.
177. Sotgiu G, Ferrara G, Matteelli A, et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 2009; 33: 871-881.
178. Jacobson KR, Tierney DB, Jeon CY, et al. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51: 6-14.
179. Migliori GB, Lange C, Girardi E, et al. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Eur Respir J 2008; 31: 904-905.
180. Osler W. The home treatment of consumption. Md Med J 1900; 43: 8-12.